Nuvation Bio Q2 net loss $59M; IBTROZI launch with 70 patients in 7 weeks

Nuvation Bio Inc.

2025-Q2 EPS reported -$0.33 revenue$7,917,000

FDA approved IBTROZI (taletrectinib) for ROS1+ NSCLC on June 11; 70 patients started by July 31.
Cash, equivalents and marketable securities $607.7M; received $200M non-dilutive financing from Sagard.
Product revenue net $1.2M from IBTROZI for 13 days of sales; collaboration revenue $3.6M (up from $1.4M).
Net loss $59M ($0.17/sh) vs $462.5M ($1.89) in prior year which included AnHeart acquisition cost.
NCCN guidelines added taletrectinib as preferred agent across lines of therapy for ROS1+ NSCLC.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.